SCHEDULE 13D/A

BRIDGEBIO PHARMA INC

Common Stock, par value $0.001 per share · CUSIP: 10806X102

Event date: 2025-08-14

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• VIKING GLOBAL INVESTORS LPReported CIK 0001103804

  Shares: 17,780,183 · Class: 9.3%

• VIKING GLOBAL PERFORMANCE LLCReported CIK 0001132625

  Shares: 213,000 · Class: 0.1%

• Viking Global Equities II LPReported CIK 0001413378

  Shares: 4,260 · Class: 0%

• Viking Global Equities Master Ltd.Reported CIK 0001759530

  Shares: 208,740 · Class: 0.1%

• Viking Long Fund GP LLCReported CIK 0001621607

  Shares: 77,532 · Class: 0.04%

• Viking Long Fund Master Ltd.Reported CIK 0001621596

  Shares: 77,532 · Class: 0.04%

• Viking Global Opportunities Parent GP LLCReported CIK 0001886738

  Shares: 17,489,651 · Class: 9.1%

• Viking Global Opportunities GP LLCReported CIK 0001629476

  Shares: 17,489,651 · Class: 9.1%

• Viking Global Opportunities Portfolio GP LLCReported CIK 0001629472

  Shares: 17,489,651 · Class: 9.1%

• Viking Global Opportunities Illiquid Investments Sub-Master LPReported CIK 0001629482

  Shares: 17,456,849 · Class: 9.1%

• Viking Global Opportunities Liquid Portfolio Sub-Master LPReported CIK 0001629483

  Shares: 32,802 · Class: 0.02%

• HALVORSEN OLE ANDREASReported CIK 0001133006

  Shares: 18,602,920 · Class: 9.7%

• Ott David C.Reported CIK 0001621842

  Shares: 18,602,920 · Class: 9.7%

• Shabet Rose SharonReported CIK 0001711393

  Shares: 18,602,920 · Class: 9.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.